As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Lifeward Ltd. The largest reported stake is Oramed Pharmaceuticals Inc.'s, at 49.9%. 2 filings are on record since July 1, 2025 (Schedule 13D, May 14, 2026).
Sell to companies like Lifeward Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lifeward Ltd. has 2 Schedule 13D or 13G filings on record since 2025-07-01. 1 holder's latest filing reports 5% or more of ordinary shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | 49.9% | 1,528,221 | SCHEDULE 13D, 2026-05-14 | 2026-03-25 |
| 4.99% | 819,443 | SCHEDULE 13G, 2025-07-01 | 2025-06-25 |
Holding shares or following this stake? See who's behind Lifeward Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Lifeward Ltd. and the records around it.
Lifeward Ltd. elsewhere on the record
- Leadership changes Aug 2026
- Company profile and every filing Jul 2026
- Form D filing Jul 2026
- Form D filing Apr 2026
- Acquisition Mar 2026
- IPO filing Jun 2025
- Who owns it
Companies that share a holder
- Oramed Pharmaceuticals Inc. also filed stake reports on 2 other companies: Nano Dimension Ltd. (Jul 2026), Scilex Holding Co (Feb 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch Lifeward Ltd.
Get an email when Lifeward Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lifeward Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lifeward Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lifeward Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Oramed Pharmaceuticals Inc.
Share Purchase Agreement On January 12, 2026, the Reporting Person entered into that certain Share Purchase Agreement (as amended, the "Share Purchase Agreement"), by and among the Reporting Person, the Issuer and Oratech Pharma, Inc. ("Oratech"), which was wholly-owned by the Reporting Person. Pursuant to the Share Purchase Agreement, the Issuer agreed to acquire all of the outstanding equity interests in Oratech from the Reporting Person in consideration for (A) the Issuer issuing to the Reporting Person a number of Ordinary Shares and pre-funded warrants (the "Pre-Funded Warrants") to purchase a number of Ordinary Shares equal to 49.99% of the Issuer's fully diluted equity capitalization, (B) the Issuer issuing to the Reporting Person warrants (the "Share Purchase Warrants") to purchase Ordinary Shares, and (C) certain ongoing revenue-based payments (the "Revenue Sharing Payments") equal to 4% of the Net Revenue (as defined in the Share Purchase Agreement) of the Issuer's ReWalk Personal Exoskeleton products and related extended warranties, until the earliest to occur of (i) the date that is 10 years after the closing of the Share Purchase Transaction (as defined below), (ii) the date on which the Reporting Person has received the Maximum Amount (as defined in the Share Purchase Agreement) of the Revenue Sharing Payments, or (iii) the first date on which the Issuer market capitalization equals or exceeds $200 million (collectively, the "Share Purchase Transaction"). On …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-01 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-05-14 | Oramed Pharmaceuticals Inc. | 49.9% | SCHEDULE 13D |
Questions about who owns Lifeward Ltd.
Who owns Lifeward Ltd.?
On this page, one holder's latest ownership filing reports 5% or more of Lifeward Ltd.: Oramed Pharmaceuticals Inc. (49.9%, Schedule 13D, filed 2026-05-14).
When did Oramed Pharmaceuticals Inc. buy into Lifeward Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Oramed Pharmaceuticals Inc. on this page is the Schedule 13D, filed 2026-05-14, reporting 49.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Lifeward Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Leadership change: Ronen Tsimerman appointed, Chief Financial Officer | — | Leadership changes | Source |
| October 1, 2026 | Leadership change: Josh Hexter appointed, Chief Executive Officer | — | Leadership changes | Source |
| August 31, 2026 | Leadership change: Mark Grant departs, President and Chief Executive Officer, and 1 more | — | Leadership changes | Source |
| August 20, 2026 | Leadership change: Yonason Greenwald appointed, and 2 more | — | Leadership changes | Source |
| August 14, 2026 | Leadership change: Almog Adar departs, Chief Financial Officer | — | Leadership changes | Source |
| July 8, 2026 | Form D, private offering | $11.16M sold | Form D page | Source |
| April 23, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 2, 2026 | Form D, private offering | $20M sold | Form D page | Source |
| March 25, 2026 | Acquired Oratech Ltd. | — | Acquisition | Source |
| June 26, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| June 25, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 20, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
The newest 12 of 15 records.
Lifeward Ltd.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Lifeward Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.